Intermittent withdrawal of oxaliplatin for alleviating neurotoxicity during oxaliplatin-based chemotherapy for Japanese patients with inoperable or metastatic colorectal cancer: A phase 2 multicenter study

Shunsuke Kato, Hiroo Imai, Makio Gamoh, Takenori Takahata, Hisatsugu Ohori, Katsuhiro Yasuda, Tomohito Niitani, Yasuko Murakawa, Kenji Amagai, Hideki Isobe, Yoshiaki Shindo, Michio Kuroki, Yasuhiro Sakamoto, Hideki Shimodaira, Takashi Yoshioka, Chikashi Ishioka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Oxaliplatin-based chemotherapy is a well-established regimen for patients with inoperable and metastatic colorectal cancer. However, one of the major limitations of oxaliplatin-based chemotherapy is sensory neuropathy. It was previously reported that introduction of intermittent oxaliplatin treatment to an oxaliplatin-based regimen has a significant benefit on efficacy or safety. Here, we prospectively assessed whether efficacy and safety of first-line chemotherapy for advanced colorectal cancer are achieved by introduction of withdrawal of oxaliplatin treatment for a certain period (intermittent oxaliplatin treatment). The primary endpoint of the present study is to assess the progression free survival time on patients treated with chemotherapy (mFOLFOX6 (levofolinate, 5-fluorouracil and oxaliplatin combination therapy) plus bevacizumab or CapeOX (oxaliplatin and capecitabine combination therapy) plus bevacizumab) with intermittent oxaliplatin treatment. Bevacizumab is a humanized anti-vascular endothelial growth factor antibody. Median progression-free survival by the mFOLFOX6 plus bevacizumab with intermittent oxaliplatin treatment or the CapeOX plus bevacizumab with intermittent oxaliplatin treatment were 10.6 months (95% confidential interval [CI], 8.3-13.4 months) or 8.0 months (95% CI, 4.2-16.8 months), respectively. Overall response rate by the mFOLFOX6 plus bevacizumab with intermittent oxaliplatin treatment or CapeOX plus bevacizumab with intermittent oxaliplatin treatment was 55.1% or 42.1%, respectively. Grade 3 or 4 neuropathy was observed in 4.1% or 10.5% of patients treated with mFOLFOX6 plus bevacizumab with intermittent oxaliplatin treatment or CapeOX plus bevacizumab with intermittent oxaliplatin treatment, respectively. Introduction of intermittent oxaliplatin treatment has improved severe neuropathy in mFOLFOX6 plus bevacizumab regimen without reducing treatment efficacy.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalTohoku Journal of Experimental Medicine
Volume245
Issue number1
DOIs
Publication statusPublished - 2018 May

Keywords

  • CapeOX plus bevacizumab
  • Colorectal cancer
  • Intermittent oxaliplatin treatment
  • MFOLFOX6 plus bevacizumab
  • Neuropathy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Intermittent withdrawal of oxaliplatin for alleviating neurotoxicity during oxaliplatin-based chemotherapy for Japanese patients with inoperable or metastatic colorectal cancer: A phase 2 multicenter study'. Together they form a unique fingerprint.

  • Cite this